Tag: Spravato
The Spravato Controversy: A Row Over the Drug’s Efficacy Compels...
The UK's drug regulator rejected Janssen's esketamine nasal spray. Why did the US FDA approve it?
John Read – UK Esketamine Approval – Not so Fast
An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.
Are Regulatory Bodies Prioritising Drug Company Interests Over Public Safety?
The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.
